| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | hyperforin | CTRPv2 | pan-cancer | AAC | 0.082 | 0.03 |
| mRNA | ML311 | CTRPv2 | pan-cancer | AAC | 0.064 | 0.04 |
| mRNA | BRD-K97651142 | CTRPv2 | pan-cancer | AAC | 0.072 | 0.05 |
| mRNA | BRD-K34485477 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.05 |
| mRNA | CIL41 | CTRPv2 | pan-cancer | AAC | 0.093 | 0.06 |
| mRNA | MLN2238 | CTRPv2 | pan-cancer | AAC | 0.062 | 0.06 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | 0.062 | 0.06 |
| mRNA | BRD-K94991378 | CTRPv2 | pan-cancer | AAC | 0.069 | 0.07 |
| mRNA | nakiterpiosin | CTRPv2 | pan-cancer | AAC | 0.059 | 0.07 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.066 | 0.07 |